Caas Capital Management LP Has $946,000 Position in Novo Nordisk A/S (NYSE:NVO)

Caas Capital Management LP lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 52.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 11,000 shares of the company’s stock after buying an additional 3,800 shares during the quarter. Caas Capital Management LP’s holdings in Novo Nordisk A/S were worth $946,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S during the third quarter worth about $28,000. Capital Performance Advisors LLP bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $42,000. Albion Financial Group UT grew its stake in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares in the last quarter. Sound Income Strategies LLC lifted its position in shares of Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after purchasing an additional 243 shares in the last quarter. Finally, Carolina Wealth Advisors LLC acquired a new position in Novo Nordisk A/S during the third quarter worth $48,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 2.1 %

Shares of Novo Nordisk A/S stock opened at $82.64 on Tuesday. The firm’s 50 day moving average is $93.56 and its 200 day moving average is $112.87. The firm has a market capitalization of $370.85 billion, a PE ratio of 26.74, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Analyst Upgrades and Downgrades

NVO has been the subject of several analyst reports. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.